Enliven: Challenges in Cancer Detection and Therapy | Open Access Journals | Open Access Articles


Zhiwei Hu, PhD

Editorial Board Member

"Dr. Zhiwei Hu is an associate professor in the Department of Surgery of The Ohio State University College of Medicine. Prior to this position, he was a Research Scientist (Research Associate Professor) in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine. Dr. Hu is one of first few scientists who proposed to target both the tumor cells and tumor neovasculature. Subsequently he successfully co-invented/developeda novel Icon molecule for dual neovascular- and cancer cell-targeted immunotherapy. As co-inventor, he holds 4 US patents of Icon and its uses. The Icon has been tested for immunotherapy of cancer, aged-related macular degeneration (AMD) and endometriosis in preclinical studies. Icon immunotherapy is currently being tested in Phase I clinical trials for AMD patients. Recently his laboratory developed another targeted therapeutics, namely factor VII (fVII)-targeted photodynamic therapy (fVII-tPDT) using fVII peptides-conjugated photosensitizers for cancer (including chemoresistant cancer) and AMD. He is a member of the Yale Cancer Center, American Association for Cancer Research, and The American Association of Immunologists. He is an Adjunct Professor of Sichuan University School of Medicine and Nanchang University School of Medicine in China, and a Scientific Advisor for Iconic Therapeutics Inc. In 2011 he was elected as Vice President of the Chinese Association for Science and Technology in Connecticut (CAST-CT). Dr. Hu is a peer reviewer for numerous scientific journals in immunology, photodynamic therapy and cancer research and serves as an editorial board member of several journals. "